Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.
Gründer
G
G
Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Aachen, RWTH Aachen, Germany. ggruender@ukaachen.de
Kungel
M
M
Ebrecht
M
M
Göröcs
T
T
Modell
S
S
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D002540:Cerebral Cortex / Q000187:drug effects*; D003342:Corpus Striatum / Q000187:drug effects; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008032:Limbic System / Q000187:drug effects*; D008636:Mesencephalon / Q000187:drug effects*; D009434:Neural Pathways / Q000187:drug effects; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D058830:Serotonin 5-HT2 Receptor Antagonists; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D058830:Serotonin 5-HT2 Receptor Antagonists; D000068180:Aripiprazole